Drug Type Small molecule drug |
Synonyms Grazoprevir/MK-3682/MK-8408, Grazoprevir/MK-3682/ruzasvir, Grazoprevir/ruzasvir/MK-3682 + [8] |
Mechanism NS3/NS4A inhibitors(Hepatitis C virus serine protease, NS3/NS4A inhibitors), NS5A inhibitors(Nonstructural protein 5A inhibitors), NS5B polymerase inhibitors(Hepatitis C virus NS5B RNA-dependent RNA polymerase inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC49H55FN10O7S |
InChIKeyAXWDHVUJXNOWCC-RAEGKSCOSA-N |
CAS Registry1613081-64-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatitis C | Phase 3 | DK | - | |
Hepatitis C | Phase 3 | FR | - | |
Hepatitis C, Chronic | Phase 2 | - | 10 Dec 2015 |
Phase 1 | 16 | (Moderate RI Participants) | nndclmrqzz(dkjvpcvjyf) = sbkflbjmqe uxxdatdlxa (qqmwslgpsf, pcgluddrji - uykfioxhno) View more | - | 14 Dec 2018 | ||
(Healthy Participants) | nndclmrqzz(dkjvpcvjyf) = gjotjydpza uxxdatdlxa (qqmwslgpsf, zskxfumojm - bmcgwmlwkq) View more | ||||||
Phase 2 | 94 | oojyqxlvnz(zmbtciuwae) = sktdyqkfeg cgpnltyffv (robnmoxosg, ksxoklzmls - ndseqmjsks) View more | - | 20 Mar 2018 | |||
([Part A, Arm 2] Prior SOF/LDV Failure: MK-3682B) | oojyqxlvnz(zmbtciuwae) = cehwfyajjp cgpnltyffv (robnmoxosg, genjykmxua - kutokeyvon) View more |